Shares of

Kendle

were among the best-performing health-related stocks Tuesday, climbing 19% after the clinical research company posted better-than-expected fourth-quarter results.

Kendle earned $3.7 million, or 25 cents a share, on total sales of $66.5 million. Excluding items, the company earned $4.5 million, or 31 cents a share. Analysts polled by Thomson First Call expected earnings of 26 cents a share. During the year-earlier period, the company earned $2.1 million, or 16 cents a share, on sales of $59.2 million. Shares were trading up $4.52 to $28.92.

Cutera

(CUTR) - Get Report

tumbled 13% after the maker of lasers and other light-based aesthetic systems posted solid fourth-quarter earnings but warned that first-quarter results would fall short of forecasts. The company earned $5.8 million, or 41 cents a share, in the fourth quarter, up from $2.1 million, or 16 cents a share, a year earlier. Sales rose to $24 million from $16.1 million. The results beat analysts' expectation for earnings of 30 cents a share and sales of $22.2 million.

For the first quarter, though, Cutera sees earnings of $1.6 million, or 11 cents a share, before stock-based compensation costs. Analysts project earnings of 19 cents a share. The company predicts sales of $19 million, below Wall Street's projection of $20.3 million. Shares were trading down $3.80 to $26.06.

Shares of

Micrus Endovascular

fell 3% after the medical device maker posted third-quarter results that were lower than expected. The company reported a loss of $1.7 million, or 12 cents a share, on sales of $8.1 million. Analysts expected a smaller loss of 7 cents a share and sales of $8.5 million. In the year-earlier period, the company recorded a loss of $1.9 million, or $1.35 a share, on sales of $5.7 million.

Looking ahead, Micrus continues to expect fiscal 2006 sales of $31 million to $33 million. Micrus also continues to expect a narrower operating loss compared with fiscal 2005. Analysts project a full-year loss of 56 cents a share and sales of $32.3 million. Shares were trading down 29 cents to $9.16.

Matrixx Initiatives

rose 2% after the company posted better-than-expected fourth-quarter results and forecast 2006 sales above expectations. The company, a maker of health care products such as the Zicam cold remedy, reported a fourth-quarter loss of $3 million, or 31 cents a share, on sales of $44 million. Excluding items, the company earned $1.6 million, or 16 cents a share. Analysts expected a loss of 40 cents a share and sales of $41.8 million. During the year-earlier quarter, the company earned $1.7 million, or 17 cents a share, on sales of $27 million.

Matrixx projects 2006 sales growth of 25% to 35%, or sales of $113 million to $122 million. The company predicts that earnings will grow by 15% to 25%, which would imply earnings of $8.7 million to $9.5 million. Analysts project earnings of 99 cents a share and sales of $107.4 million. Shares were up 45 cents to $22.74.

Advanced Medical Optics

(EYE) - Get Report

fell 5% after the eye-care products company posted fourth-quarter earnings that fell a penny short of expectations. The company earned $2.3 million, or 3 cents a share, on sales of $252.8 million. Excluding items, the company earned 40 cents a share. Analysts expected earnings of 41 cents a share and sales of $264.3 million. During the year-earlier quarter, the company earned $10.1 million, or 26 cents a share, on sales of $224.7 million. Excluding items, the company would have earned 55 cents a share a year earlier.

Looking ahead, Advanced Medical Optics sees 2006 adjusted earnings of $2.20 to $2.30 a share, above analysts' average forecast of $2.20 a share. The company forecast sales of $1.02 billion to $1.04 billion, compared with Wall Street's projection of $1.04 billion. For 2007, Advanced Medical sees earnings of at least $2.65 a share and sales of $1.1 billion to $1.12 billion. Analysts project 2007 earnings of $2.64 a share, with sales of $1.12 billion. The company's shares were down 2.05 to $41.55.

Other health-care volume movers included

Pfizer

(PFE) - Get Report

, down 4 cents to $25.54;

Genta

, down 8 cents to $2.63;

Schering-Plough

, up 8 cents to $18.43;

Amgen

(AMGN) - Get Report

, up $1.11 to $72.25;

Bristol-Myers Squibb

(BMY) - Get Report

, down 7 cents to $22.84;

Johnson & Johnson

(JNJ) - Get Report

, up 54 cents to $59.04;

Boston Scientific

(BSX) - Get Report

, up 1 cent to $21.78;

Elan

(ELN)

, up 7 cents to $14.09;

Merck

(MRK) - Get Report

, up 25 cents to $34.56; and

Genentech

, up $2.02 to $83.62.